Brazilian Journal of Infectious Diseases (May 2014)

Detection of hepatitis B virus A1762T/G1764A mutant by amplification refractory mutation system

  • Yong-Zhong Wang,
  • Zhen Zhu,
  • Hong-Yu Zhang,
  • Min-Zhi Zhu,
  • Xin Xu,
  • Chun-Hua Chen,
  • Long-Gen Liu

Journal volume & issue
Vol. 18, no. 3
pp. 261 – 265

Abstract

Read online

Objective: To study the role of hepatitis B virus with A1762T/G1764A double mutation in liver cirrhosis and hepatocellular carcinoma, and create a sensitive, fast, accurate assay for detection of A1762T/G1764A double mutation. Methods: We developed an accurate and fast real-time amplification refractory mutation system to detect A1762T/G1764A double mutation. Cloned hepatitis B virus genome was used as a control. Assay sensitivity was determined by serial dilution and mixed template experiments. Specificity was determined by cross experiments with wild and mutant hepatitis B virus. Fifty clinical samples were tested by the real-time amplification refractory mutation system and the results were compared with sequencing. Results: The real-time amplification refractory mutation system had a sensitivity of 100 copies of virus with these mutations, and 0.1% weak population virus with double mutation could be found in mixtures. A total of 50 randomly collected clinical samples were detected by real-time amplification refractory mutation system, and the results were consistent with those by DNA sequencing. Hepatitis B virus genotype C was more prevalent in 39 of 50 samples than genotype B (11 samples), and about 75% of genotype C carried a double mutation compared to 45% of genotype B. However, the percentage of A1762T/G1764A double mutation in hepatitis B e antigen-negative (58.3%) samples was almost the same as in hepatitis B e antigen-positive (61%) samples. Conclusion: The real-time amplification refractory mutation system is sensitive and specific for detection of hepatitis B virus double mutation. Keywords: Hepatitis B virus, Basal core promoter mutations, Amplification refractory mutation system, PCR